- Home
- NVO
NVO
Novo Nordisk A/S
as 11-20-2024 4:00pm EST
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
| Founded: | 1923 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 530.0B | IPO Year: | N/A |
| Target Price: | $139.33 | AVG Volume (30 days): | 6.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 3.17 | EPS Growth: | 26.84 |
| 52 Week Low/High: | $94.73 - $148.15 | Next Earning Date: | 11-06-2024 |
| Revenue: | $40,469,178,712 | Revenue Growth: | 26.15% |
| Revenue Growth (this year): | 25.02% | Revenue Growth (next year): | 20.47% |
Latest Novo Nordisk A/S News
NVO Breaking Stock News: Dive into NVO Ticker-Specific Updates for Smart Investing
Barrons.com
3 hours ago
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
Quartz
17 hours ago
Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound
MT Newswires
19 hours ago
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
MT Newswires
a day ago
Update: Novo Nordisk Launches Weight-Loss Drug Wegovy in China
Motley Fool
a day ago
Is Novo Nordisk Stock a Buy Right Now?
Barrons.com
a day ago
RFK Jr. Sparks New Worries About Obesity Drugs. Here’s What Investors Should Focus on Instead.
MT Newswires
2 days ago
Sector Update: Health Care Stocks Decline
MT Newswires
2 days ago
Sector Update: Health Care Stocks Mixed Tuesday Afternoon
Compare NVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVO Novo Nordisk A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.